PAREXEL INTERNATIONAL OPENS NEW OFFICE IN BEDMINSTER, NEW JERSEY
BOSTON, MA, May 2, 2001 — PAREXEL International Corporation, (Nasdaq: PRXL) one of the world’s largest Contract Research Services Organizations, today announced the official opening of its newest U.S. site in Bedminster, New Jersey. Located in New Jersey’s “Pharmaceutical Belt”, the office is in close proximity to numerous pharmaceutical and biotechnological companies. The facility provides, among other clinical research services, the management and performance of appropriate safety surveillance of client procedures for compliance with regulatory guidelines for product-related issues. This site will be the central hub for PAREXEL International’s North American Pharmacovigilance Services. The office is staffed with safety professionals with an expertise in providing surveillance for approved products.
"All companies conducting clinical research or marketing medical products have a regulatory obligation to monitor and evaluate safety concerns,” said Warren Stern, Ph.D., Senior Vice President Scientific and Medical Services. “With this new site in Bedminster, PAREXEL further expands its pharmacovigilance solutions and will draw on its extensive medical and clinical expertise with a goal toward ensuring that clients comply with pharmacovigilance guidelines globally."
The new Bedminster office is located at 1420 State Highway 206, North, Suite 140, Bedminster, New Jersey. The office telephone number is (908) 470-0321 and fax is (908) 470-0279.
PAREXEL is one of the largest contract pharmaceutical outsourcing organizations in the world, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. With a commitment to providing solutions that expedite time-to-market and peak market penetration, PAREXEL has developed significant expertise in clinical trials management, data management, biostatistical analysis, medical marketing, clinical pharmacology, regulatory and medical consulting, industry training and publishing and other drug development consulting services. Its newest subsidiary, Perceptive Informatics, Inc., provides a variety of technology products and services, including web-based portal solutions and voice and data systems, which are designed to accelerate and enhance the clinical development and launch processes. The Company’s integrated services, therapeutic area depth and sophisticated information technology, along with its experience in global drug development and product launch services, represent key competitive strengths. Headquartered near Boston, MA, PAREXEL operates in 51 locations throughout 29 countries around the world, and has approximately 4,550 employees.
This release may contain "forward-looking" statements regarding future results and events, including statements regarding expected financial results, future growth and customer demand that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "expects", "intends", "appears" and similar expressions are intended to identify forward-looking statements. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the cancellation, revision, or delay of contracts, including those contracts in backlog; the Company's dependence on certain industries and clients; the Company's ability to manage growth and its ability to attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; government regulation of certain industries and clients; competition and consolidation within the pharmaceutical industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Form 10-Q for the period ended December 31, 2000, as filed with the Securities and Exchange Commission.